AMERICAN ASSOCIATION FOR CANCER RESEARCH for AMERICAN ASSOCIATION FOR CANCER RESEARCH
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
FY 2023 Appropriations for the National Institutes of Health FY 2023 Appropriations for the Centers for Disease Control and Prevention FY 2023 Appropriations for the Food and Drug Administration FY 2023 Appropriations for the Congressionally Directed Medical Research Programs at the Department of Defense
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANA MILLER ACTON | — |
| MATTHEW GONTARCHICK New | — |
| MARC JOHNSON | — |
Medical/Disease Research/Clinical Labs MED
Cancer research Oncology product review at the FDA Pediatric research and cancer care Clinical trials Diversity in clinical trials
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANA MILLER ACTON New | — |
| MATTHEW GONTARCHICK New | — |
| MARC JOHNSON | — |
Tobacco TOB
Tobacco control measures E-cigarette regulation
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANA MILLER ACTON New | — |
| MATTHEW GONTARCHICK New | — |
| MARC JOHNSON | — |
Health Issues HCR
Cancer health disparities HPV-related cancers - prevention, screening, diagnosis and treatment HPV vaccination Cancer survivorship
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANA MILLER ACTON New | — |
| MATTHEW GONTARCHICK New | — |
| MARC JOHNSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.